Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103038 · ClinicalTrials.gov registry record · NA
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
A NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT00103038: Completed NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma, sponsored by OHSU Knight Cancer Institute.
NCT00103038 is a NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 155 participants, above the 84-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (85% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103038, a NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose brain tumors and find out how far the disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It may help visualize the blood flow going through the tumor better than the standard substance gadolinium-based contrast agent.
Primary Outcome
Appropriate descriptive statistics (mean, standard deviation, minimum, median, and maximum) will be estimated for the imaging parameters Ktrans. Frequency distributions of each parameter will also be described to assess normality. Pearson's correlation coefficients will be estimated to describe potential relationships among these various measures.
Conditions Studied
Interventions
- DRUG Ferumoxytol
- DRUG Gadolinium
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- PROCEDURE 3 Tesla Magnetic Resonance Imaging
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2004-06-04 |
| Est. Completion | 2016-06-10 |
| Phase | NA |
What the finished NCT00103038 record still lists
NCT00103038 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 84-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (85% higher).
The record links to 3 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 5 interventions - of which Ferumoxytol is the first listed.
NCT00103038 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00103038 about?
NCT00103038 is a clinical study titled "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases". This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help...
What is the current status of trial NCT00103038?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2004-06-04. Estimated completion is 2016-06-10.
What conditions does trial NCT00103038 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Malignant Glioma, Central Nervous System Lymphoma.
What interventions are being tested in trial NCT00103038?
The interventions under investigation include: Ferumoxytol (DRUG), Gadolinium (DRUG), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), 3 Tesla Magnetic Resonance Imaging (PROCEDURE), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00103038?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103038 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00103038's enrollment target sits among peer trials
155 8th of 43 higher than 36 of 43 other Metastatic Malignant Neoplasm in the Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm in the Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
RECRUITING · NA
-
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
RECRUITING · NA
-
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
RECRUITING · NA
-
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
RECRUITING · NA
-
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
ACTIVE NOT RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI